CLSD · As filed with the SEC
Clearside Biomedical balance sheet, by quarter
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 6,801,000 | 9,376,000 | 13,628,000 | 20,020,000 | 13,888,000 | 18,238,000 | 35,355,000 | 28,920,000 |
| Short-term investments | — | — | — | — | 9,703,000 | 11,122,000 | — | — |
| Accounts receivable | 266,000 | 816,000 | 1,538,000 | 507,000 | 788,000 | 0 | 0 | 170,000 |
| Prepaid expenses | 1,187,000 | 1,580,000 | 721,000 | 734,000 | 721,000 | 364,000 | 567,000 | 722,000 |
| Other current assets | 0 | 13,000 | 77,000 | 13,000 | 13,000 | 44,000 | 193,000 | 311,000 |
| Total current assets | 8,254,000 | 11,785,000 | 15,964,000 | 21,274,000 | 25,113,000 | 29,768,000 | 36,115,000 | 30,123,000 |
| Property and equipment, net | 2,981,000 | 3,065,000 | 3,149,000 | 3,225,000 | 3,351,000 | 3,400,000 | 3,194,000 | 2,996,000 |
| Operating lease right-of-use asset | 376,000 | 452,000 | 525,000 | 597,000 | 667,000 | 736,000 | 803,000 | 869,000 |
| Other assets | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 |
| Total assets | 11,641,000 | 15,332,000 | 19,668,000 | 25,126,000 | 29,161,000 | 33,934,000 | 40,142,000 | 34,018,000 |
| Liabilities and stockholders' deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable (includes $491 to a related party as of December 31, 2024) | 796,000 | 1,129,000 | 1,914,000 | 1,452,000 | 2,361,000 | 1,576,000 | 1,363,000 | 2,205,000 |
| Accrued liabilities (includes $304 to a related party as of December 31, 2024) | 1,590,000 | 1,537,000 | 2,720,000 | 2,967,000 | 2,859,000 | 3,703,000 | 4,070,000 | 4,169,000 |
| Current portion of operating lease liabilities | 384,000 | 381,000 | 378,000 | 375,000 | 373,000 | 370,000 | 367,000 | 364,000 |
| Deferred revenue | — | — | — | 0 | 0 | 225,000 | 150,000 | 75,000 |
| Total current liabilities | 2,770,000 | 3,047,000 | 5,012,000 | 4,794,000 | 5,593,000 | 5,874,000 | 5,950,000 | 6,813,000 |
| Liability related to the sales of future royalties, net | 61,167,000 | 55,702,000 | 53,440,000 | 51,767,000 | 49,188,000 | 46,731,000 | 44,391,000 | 41,988,000 |
| Warrant liabilities | 1,192,000 | 4,765,000 | 6,485,000 | 6,692,000 | 8,757,000 | 9,121,000 | 11,039,000 | — |
| Operating lease liabilities | 62,000 | 152,000 | 241,000 | 328,000 | 412,000 | 493,000 | 572,000 | 649,000 |
| Other non-current liabilities | — | — | — | 400,000 | — | — | — | 480,000 |
| Other non-current liabilities | 400,000 | 400,000 | 400,000 | — | 0 | 0 | 0 | — |
| Total liabilities | 65,591,000 | 64,066,000 | 65,578,000 | 63,981,000 | 63,950,000 | 62,219,000 | 61,952,000 | 49,930,000 |
| Stockholders' deficit: | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at September 30, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value; 26,666,666 and 13,333,333 shares authorized at September 30, 2025 and December 31, 2024, respectively; 5,233,981 and 5,105,216 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 78,000 | 78,000 | 77,000 | 77,000 | 75,000 | 74,000 | 74,000 | 63,000 |
| Additional paid-in capital | 319,937,000 | 319,181,000 | 317,511,000 | 316,343,000 | 313,100,000 | 311,922,000 | 310,802,000 | 304,948,000 |
| Accumulated deficit | (373,965,000) | (367,993,000) | (363,498,000) | (355,275,000) | (347,969,000) | (340,280,000) | (332,686,000) | (320,923,000) |
| Accumulated other comprehensive gain | — | — | — | — | 5,000 | (1,000) | — | — |
| Total stockholders` deficit | (53,950,000) | (48,734,000) | (45,910,000) | (38,855,000) | (34,789,000) | (28,285,000) | (21,810,000) | (15,912,000) |
| Total liabilities and stockholders` deficit | 11,641,000 | 15,332,000 | 19,668,000 | 25,126,000 | 29,161,000 | 33,934,000 | 40,142,000 | 34,018,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.